title: Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.
abstract: We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.
authors.affiliation: Department of Neurology, District Medical Center, University of Regensburg, Regensburg, Germany. peter.hau@medbo.de
authors.forename: P
authors.initials: P
authors.lastname: Hau
authors.forename: D
authors.initials: D
authors.lastname: Koch
authors.forename: T
authors.initials: T
authors.lastname: Hundsberger
authors.forename: E
authors.initials: E
authors.lastname: Marg
authors.forename: B
authors.initials: B
authors.lastname: Bauer
authors.forename: R
authors.initials: R
authors.lastname: Rudolph
authors.forename: M
authors.initials: M
authors.lastname: Rauch
authors.forename: A
authors.initials: A
authors.lastname: Brenner
authors.forename: P
authors.initials: P
authors.lastname: Rieckmann
authors.forename: J
authors.initials: J
authors.lastname: Schuth
authors.forename: T
authors.initials: T
authors.lastname: Jauch
authors.forename: H
authors.initials: H
authors.lastname: Koch
authors.forename: U
authors.initials: U
authors.lastname: Bogdahn
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018572:Disease-Free Survival; D005240:Feasibility Studies; D005260:Female; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D016019:Survival Analysis; D015996:Survival Rate; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide